Charge heterogeneity: Basic antibody charge variants with increased binding to Fc receptors

ABSTRACT We identified active isoforms of the chimeric anti-GD2 antibody, ch14.18, a recombinant antibody produced in Chinese hamster ovary cells, which is already used in clinical trials.1,2,3 We separated the antibody by high resolution ion-exchange chromatography with linear pH gradient elution into acidic, main and basic charge variants on a preparative scale yielding enough material for an in-depth study of the sources and the effects of microheterogeneity. The binding affinity of the charge variants toward the antigen and various cell surface receptors was studied by Biacore. Effector functions were evaluated using cellular assays for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. Basic charge variants showed increased binding to cell surface receptor FcγRIIIa, which plays a major role in regulating effector functions. Furthermore, increased binding of the basic fractions to the neonatal receptor was observed. As this receptor mediates the prolonged half-life of IgG in human serum, this data may well hint at an increased serum half-life of these basic variants compared to their more acidic counterparts. Different glycoform patterns, C-terminal lysine clipping and N-terminal pyroglutamate formation were identified as the main structural sources for the observed isoform pattern. Potential differences in structural stability between individual charge variant fractions by nano differential scanning calorimetry could not been detected. Our in-vitro data suggests that the connection between microheterogeneity and the biological activity of recombinant antibody therapeutics deserves more attention than commonly accepted.

[1]  D. James,et al.  Control of Recombinant Monoclonal Antibody Effector Functions by Fc N‐Glycan Remodeling in Vitro , 2005, Biotechnology progress.

[2]  Kerry Parsons,et al.  Targeted Immunotherapy for High-Risk Neuroblastoma—The Role of Monoclonal Antibodies , 2013, The Annals of pharmacotherapy.

[3]  Damian Houde,et al.  Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding* , 2010, Molecular & Cellular Proteomics.

[4]  Hongcheng Liu,et al.  In vitro and in vivo modifications of recombinant and human IgG antibodies , 2014, mAbs.

[5]  M. Schenerman,et al.  Advances in the assessment and control of the effector functions of therapeutic antibodies , 2011, Nature Reviews Drug Discovery.

[6]  Gillian Dekkers,et al.  IgG Subclasses and Allotypes: From Structure to Effector Functions , 2014, Front. Immunol..

[7]  T. Wurch,et al.  Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. , 2008, Current pharmaceutical biotechnology.

[8]  Akira Okazaki,et al.  Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. , 2007, Glycobiology.

[9]  Mahiuddin Ahmed,et al.  Engineering anti‐GD2 monoclonal antibodies for cancer immunotherapy , 2014, FEBS letters.

[10]  J. Maris,et al.  Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma , 2014, Cancer Chemotherapy and Pharmacology.

[11]  K. Brorson,et al.  Therapeutic monoclonal antibodies and consistent ends: terminal heterogeneity, detection, and impact on quality. , 2014, Current opinion in biotechnology.

[12]  E. Stadtman,et al.  Oxidation of Methionine in Proteins: Roles in Antioxidant Defense and Cellular Regulation , 2000, IUBMB life.

[13]  G. Vidarsson,et al.  IgG-effector functions: "the good, the bad and the ugly". , 2014, Immunology letters.

[14]  C. Stemmer,et al.  In vivo glyco‐engineered antibody with improved lytic potential produced by an innovative non‐mammalian expression system , 2007, Biotechnology journal.

[15]  P. Glander,et al.  Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients , 2013, mAbs.

[16]  V. Katta,et al.  Identification of isomerization and racemization of aspartate in the Asp-Asp motifs of a therapeutic protein. , 2011, Analytical biochemistry.

[17]  M. Bardor,et al.  Highly linear pH gradients for analyzing monoclonal antibody charge heterogeneity in the alkaline range: Validation of the method parameters. , 2014, Journal of chromatography. A.

[18]  Y. Saeys,et al.  The function of Fcγ receptors in dendritic cells and macrophages , 2014, Nature Reviews Immunology.

[19]  C. Pace,et al.  A summary of the measured pK values of the ionizable groups in folded proteins , 2008, Protein science : a publication of the Protein Society.

[20]  Andrew M Goetze,et al.  Assessing monoclonal antibody product quality attribute criticality through clinical studies , 2010, mAbs.

[21]  Renate Kunert,et al.  Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. , 2005, Molecular immunology.

[22]  Hongcheng Liu,et al.  Heterogeneity of monoclonal antibodies. , 2008, Journal of pharmaceutical sciences.

[23]  W. Xu,et al.  Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies , 2012, mAbs.

[24]  Hongcheng Liu,et al.  Effect of posttranslational modifications on the thermal stability of a recombinant monoclonal antibody. , 2006, Immunology letters.

[25]  M. Bardor,et al.  IRES-mediated Tricistronic vectors for enhancing generation of high monoclonal antibody expressing CHO cell lines. , 2012, Journal of biotechnology.

[26]  A. Deelder,et al.  Glycoproteomic Analysis of Antibodies , 2013, Molecular & Cellular Proteomics.

[27]  J. Bruno,et al.  Overview of Biacore Systems and Their Applications , 2006, Current protocols in protein science.

[28]  Peiqing Zhang,et al.  The sweet tooth of biopharmaceuticals: Importance of recombinant protein glycosylation analysis , 2012, Biotechnology journal.

[29]  F. Szoka,et al.  The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. , 2015, Advanced drug delivery reviews.

[30]  M. Weiss,et al.  Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2 , 2016, mAbs.

[31]  M. Bardor,et al.  Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins , 2012, Biotechnology journal.

[32]  Li Yang,et al.  Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. , 2007, Analytical biochemistry.

[33]  A. Görg,et al.  Very alkaline immobilized pH gradients for two‐dimensional electrophoresis of ribosomal and nuclear proteins , 1997, Electrophoresis.

[34]  Hongcheng Liu,et al.  Disulfide bond structures of IgG molecules , 2012, mAbs.

[35]  P. Bruhns,et al.  Contribution of Human FcγRs to Disease with Evidence from Human Polymorphisms and Transgenic Animal Studies , 2014, Front. Immunol..

[36]  J. L. Abrahams,et al.  Erythropoietin produced in a human cell line (Dynepo) has significant differences in glycosylation compared with erythropoietins produced in CHO cell lines. , 2011, Molecular pharmaceutics.

[37]  Alois Jungbauer,et al.  Highly linear pH gradients for analyzing monoclonal antibody charge heterogeneity in the alkaline range. , 2013, Journal of chromatography. A.

[38]  G. Weiner,et al.  Complement and cellular cytotoxicity in antibody therapy of cancer. , 2008, Expert opinion on biological therapy.